Literature DB >> 28839821

Biosimilars: what's around the corner?

Richard K Russell1, Peter Irving2, Chris Probert3.   

Abstract

Keywords:  INFLIXIMAB

Year:  2015        PMID： 28839821      PMCID： PMC5369612          DOI： 10.1136/flgastro-2015-100587

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  3 in total

1.  Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series.

Authors:  Yun-Seong Kang; Hyoung Ho Moon; Seung Eun Lee; Yun Jeong Lim; Hyoun Woo Kang
Journal:  Dig Dis Sci       Date:  2014-10-18       Impact factor: 3.199

2.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

3.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.

Authors:  Won Park; Pawel Hrycaj; Slawomir Jeka; Volodymyr Kovalenko; Grygorii Lysenko; Pedro Miranda; Helena Mikazane; Sergio Gutierrez-Ureña; MieJin Lim; Yeon-Ah Lee; Sang Joon Lee; HoUng Kim; Dae Hyun Yoo; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103
  3 in total
  1 in total

Review 1.  Biosimilars in paediatric inflammatory bowel disease.

Authors:  Joanna Sieczkowska-Golub; Dorota Jarzebicka; Grzegorz Oracz; Jaroslaw Kierkus
Journal:  World J Gastroenterol       Date:  2018-09-21       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.